Clinical Scorecard: Complement Inhibition Slows GA in Eyes With Wet AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (nAMD) |
| Key Mechanisms | Complement inhibition therapy |
| Target Population | Patients with existing neovascular age-related macular degeneration |
| Care Setting | Retina specialty clinics |
Key Highlights
- Complement inhibition therapy reduced GA progression by nearly 50%.
- Post-treatment GA lesion growth rate decreased from 1.5 mm² to 0.8 mm².
- Stable CNV activity observed with minimal need for therapy alteration.
- Visual acuity remained stable over a 1-year follow-up.
- Complement inhibition does not negatively impact wet AMD.
Guideline-Based Recommendations
Diagnosis
- Use optical coherence tomography (OCT) for tracking lesion size and growth.
Management
- Consider complement inhibition therapy for patients with GA and wet AMD.
Monitoring & Follow-up
- Assess CNV activity via OCT indicators and visual acuity regularly.
Risks
- Monitor for potential new signs of CNV activity post-treatment.
Patient & Prescribing Data
Patients diagnosed with nAMD prior to initiating complement therapy.
Both pegcetacoplan and avacincaptad pegol showed consistent efficacy.
Clinical Best Practices
- Initiate complement inhibition therapy in patients already diagnosed with wet AMD.
- Extend anti-VEGF treatment intervals where appropriate after complement therapy.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.